SHETH, Agam,SUNDARARAJAN, Pavithra,MILLER, Elise,MOSER, Justin David,SOCIA, Adam,WAGNER, Angela, M.
申请号：
EP15873902
公开号：
EP3237412A4
申请日:
2015.11.06
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present disclosure is directed to solid dispersion formulations comprising an NS5A inhibitor compound, elbasvir (dimethyl N,N′-([(6S)-6-phenylindolo [1,2- c][1,3]benzoxazine-3,10-diyl]bis {1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-methyl-l-oxobutane-1,2-diyl]})di-carbamate), or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and optionally a pharmaceutically acceptable surfactant. The present disclosure is also directed to solid dispersion formulations, blended compositions and pharmaceutical dosage forms containing or made from these solid dispersion formulations, and the methods for making these solid dispersion formulations, blended compositions and pharmaceutical dosage forms.
